Tag Archive | "royalty financing"

Capital Royalty announces $805m in royalty financing

Tags: ,


Capital Royalty announced the final closing of Capital Royalty Partners II with $805 million in equity financing. Read the full story

Royalty Pharma acquires interest in Fumapharm financing

Tags: ,


Royalty Pharma acquired an interest in the earn-out financing payable to the former shareholders of Fumapharm AG for $761 million in cash Read the full story

Royalty financing agreement for Fumaderm assets

Tags: ,


Royalty Pharma acquired an interest in the royalty financing earn-out payable to the former shareholders of Fumapharm AG for $761 million in cash Read the full story

The growth of synthetic royalty financing

Tags:


A recent study (report: Royalty Financing Terms and Agreements) has shown a significant increase in the use of royalty and revenues based financing as an alternative way for biotechs to raise finance Read the full story

Royalty Financing Terms and Agreements

Tags: , ,


The Royalty Financing Terms and Agreements report provides comprehensive understanding and unprecedented access to the royalty financing agreements entered into by the worlds leading biopharma companies. Read the full story

Royalty Pharma to pay Sunesis $25 million for future royalties from AML drug sales

Tags: ,


Royalty Pharma has agreed to pay Sunesis up to $25 million in return for a slice of royalties from future global sales of the latter’s Phase III-stage acute myeloid leukemia (AML) candidate vosaroxin (formerly voreloxin).  Read the full story

Dendreon sells Victrelis royalty rights for $125 million

Tags: , ,


Dendreon Corporation has agreed to sell for $125 million in cash its royalty interest related to intellectual property licensed to Schering-Plough Ltd. and Schering Corporation (collectively Schering, each now a wholly owned subsidiary of Merck & Co., Inc.) and associated with VICTRELIS (boceprevir), a treatment for chronic hepatitis C.  Read the full story

Pozen monetizes royalty stream from Trevimet for $75 million

Tags: , ,


POZEN has sold most of the future royalty and milestone payments under its collaboration and license agreement with Glaxo Read the full story

Prosidion sells DPP-IV patent rights to Royalty Pharma

Tags: ,


Prosidion has sold its patent estate and associated royalty stream rights for the use of dipeptidyl peptidase IV (DPP-IV) to Royalty Pharma for a cash payment of $609 million. Read the full story

Royalty financing agreement for dipeptidyl peptidase IV (DPP-IV) inhibitors

Tags: ,


Prosidion's patent estate and associated royalty stream relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes has been sold to Royalty Pharma for a total cash payment of USD 609 million.

The transaction is expected to close in July 2011.

Prosidion was acquired as part of Astellas' acquisition of OSI Pharmaceuticals in June 2010.

Royalty Pharma will be entitled to receive 100% of royalty payments and milestones related to the DPP-IV asset.

Additionally, Royalty Pharma will take over administration of the DPP-IV patent estate currently owned by Prosidion.

Related items:

Purchase the Dealdoc
View the Point of view article 
See this deal on the 2011 Partnering Scorecard
View this deal and thousands more at Current Agreements (subscription required)

cpbannerad300x150new1gif
rauconbadgejpg
e80banner300x150animgif
cpbannerad300x150new2gif
e80banner300x150animgif
a1banner300x150animgif